Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

ghlights

As of December 31, 2008, the Company had cash and cash equivalents totaling $9.8 million. Stockholders' equity amounted to $6.0 million as of December 31, 2008.

Non-Reliance on Previously Issued Financial Statements

On March 20, 2009, the Company's management concluded that ADVENTRX's consolidated financial statements contained in its annual report on Form 10-K for the year ended December 31, 2007 and its quarterly reports on Form 10-Q for the periods ended March 31, June 30 and September 30, 2007 and March 31, June 30 and September 30, 2008 should no longer be relied upon. ADVENTRX intends to correct the misstatements in those financial statements in its annual report on Form 10 K for the year ended December 31, 2008, which it anticipates filing before March 31, 2009.

The misstatements occurred as a result of the erroneous application of generally accepted accounting principles related to accounting for warrant liability. In connection with ADVENTRX's adoption on January 1, 2007 of Financial Accounting Standards Board Staff Position No. EITF 00-19-2, "Accounting for Registration Payment Arrangements" ("FSP EITF 00-19-2"), it erroneously retrospectively applied FSP EITF 00-19-2 to the years ended December 31, 2005 and December 31, 2006. However, the effect of this misapplication of FSP EITF 00-19-2 related entirely to non-cash line items. It had no impact on ADVENTRX's current assets (e.g., cash, cash equivalents and short-term investments) or its operating expenses and did not affect any loan covenants or other contractual requirements.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose product candidates are designed to improve the safety and commercial potential of existing cancer treatments. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the ... report to their offering. , Global Market ... on Trypsin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... SAN CARLOS, Calif., May 22 Nektar,Therapeutics (Nasdaq: ... Ph.D.,J.D. has joined the Company as Chief Operating ... responsibilities include overseeing and,managing all aspects of the ... as operations across the Company. He will also,serve ...
... Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: AVAN ... being developed for the treatment of Glioblastoma,Multiforme (GBM), ... at the 44th,Annual Meeting of the American Society ... held at McCormick Place in Chicago from May ...
... DRAD ), a leading provider of medical ... and imaging centers, today,announced the signing of a ... Medicine in Baltimore, Md., Under terms of ... read,diagnostic images for primary care physicians, throughout the ...
Cached Biology Technology:Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 2Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 3Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine 4
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... at the atomic and molecular levels nanoscale ... this level where everything happens. Alexandra Navrotsky, ... Director of its Nanomaterials in the Environment, Agriculture, and ... nanoparticles throughout her career. She presented her findings today ...
... University researcher has identified the important role that a ... could lead to a greater understanding of stem cells. ... College of Medicine, has outlined his findings in the ... Developmental Cell . The article, "CDK5RAP2 Regulates Centriole Engagement ...
... macromolecules in cells is vital to survival. Disruption ... The research group of Professor Thomas Jentsch (Leibniz ... for Molecular Medicine, MDC, Berlin-Buch) has now succeeded ... the transport and degradation of macromolecules in endosomes ...
Cached Biology News:Nanoparticle scientist speaks on new discoveries at Goldschmidt Conference 2Florida State researcher uncovers protein's role in cell division 2Researchers identify a fundamental process in lysosomal function and protein degradation 2Researchers identify a fundamental process in lysosomal function and protein degradation 3
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
For testing the AQUA technique on your MS instruments....
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Biology Products: